Vikram Purohit
Stock Analyst at Morgan Stanley
(1.94)
# 3,549
Out of 5,239 analysts
164
Total ratings
32.84%
Success rate
-3.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Overweight | $96 → $93 | $68.66 | +35.46% | 12 | May 12, 2026 | |
| CMPS COMPASS Pathways | Maintains: Overweight | $18 → $16 | $10.63 | +50.52% | 4 | Mar 25, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $98.45 | -4.52% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $19.83 | +71.46% | 3 | Oct 28, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $5.50 | +7.09% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.09 | +61.81% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $242.78 | +2.97% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $234.03 | -18.81% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.20 | +114.54% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $26.53 | +16.87% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $121.44 | -86.82% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $21.92 | -54.38% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $10.02 | +319.16% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $85.39 | -51.99% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.06 | +396.28% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.77 | +636.54% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.82 | +196.41% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $4.90 | +308.16% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $16.72 | -40.19% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.16 | +1,804.76% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $19.43 | +2.93% | 2 | Aug 5, 2020 |
Halozyme Therapeutics
May 12, 2026
Maintains: Overweight
Price Target: $96 → $93
Current: $68.66
Upside: +35.46%
COMPASS Pathways
Mar 25, 2026
Maintains: Overweight
Price Target: $18 → $16
Current: $10.63
Upside: +50.52%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $98.45
Upside: -4.52%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $19.83
Upside: +71.46%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $5.50
Upside: +7.09%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.09
Upside: +61.81%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $242.78
Upside: +2.97%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $234.03
Upside: -18.81%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.20
Upside: +114.54%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $26.53
Upside: +16.87%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $121.44
Upside: -86.82%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $21.92
Upside: -54.38%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $10.02
Upside: +319.16%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $85.39
Upside: -51.99%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.06
Upside: +396.28%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.77
Upside: +636.54%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.82
Upside: +196.41%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $4.90
Upside: +308.16%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $16.72
Upside: -40.19%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.16
Upside: +1,804.76%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $19.43
Upside: +2.93%